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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of therapeutic interventions for Bowen’s disease.
B A C K G R O U N D
Description of the condition
Bowen’s disease was first described by John T Bowen in 1912. It
is the clinical term for squamous cell carcinoma, a type of non-
melanoma skin cancer (NMSC) that is confined to the outside
layer of the skin - the epidermis (Arlette 2004). Typically, Bowen’s
Disease lesions are slow growing, non-pigmented reddish patches
with irregular edges and a yellow or white crusting or scaling sur-
face, although infrequently the lesions can be pigmented (Ragi
1988; Cox 1999; Arlette 2004). They are clearly demarcated from
the surrounding, normal skin. They are generally asymptomatic,
although larger lesions may itch (Arlette 2004). The lesions are
usually solitary, but multiple lesions do occur in 10 to 20% of
those affected (Eedy 1987; Thestrup-Ped 1988; Kovacs 1996).
Their size varies considerably, from a few millimetres to several
centimetres in diameter, with the size of the lesion being directly
related to its duration (Arlette 2004). They are usually persistent
and progressive, with a small potential for invasive malignancy
(Cox 1999).
Incidence and demographics
Bowen’s Disease can occur at any age in adults, although large
population cohort studies suggest that it is commonly diag-
nosed in older people, between 60 and 90 years old (Eedy 1987;
Thestrup-Ped 1988; Kossard 1992; Reizner 1994; Kovacs 1996;
Jaeger 1999). These studies also reveal considerable worldwide
variation in gender and body site distribution.
Generally, Bowen’s Disease occurs more commonly in women,
and varies from country to country as shown by the following
figures: 57% of cases in an Australian study (Kossard 1992), 56%
to 61% in two Danish studies respectively (Thestrup-Ped 1988;
Jaeger 1999), 54% in a Japanese study (Kovacs 1996), 74% to
80% in two studies in theUK (Eedy 1987; Cox 1994), and 63% in
a study from the USA (Reizner 1994). The exception to this pre-
dominance of Bowen’s Disease in women was reported in a study
of white people living in Hawaii where women only accounted
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for 38% of the reported cases (Reizner 1994). Although few stud-
ies have calculated incidence rates, there is considerable variation
between the rates reported in North America (15 per 100 000 in
Minneapolis, USA (Chute 1991) and in Canada 28 per 100,000
for men, and 22 per 100,000 for women (Arlette 2004) compared
to white people living in Hawaii (174 per 100,000 for men and
115 per 100,000 for women) (Reizner 1994).
In Australia, the most common sites of Bowen’s Disease lesions are
the head and neck (44%), followed by the lower limbs (30%) with
70% of lesions occurring below the knee. Australian men most
commonly have lesions on their head and necks, while Australian
women more commonly have Bowen’s Disease lesions on their
lower limbs (Kossard 1992). The head and neck regions were also
the most common site for lesions in Denmark with 59% in one
study (Thestrup-Ped 1988) and 40% in another (Jaeger 1999),
and 66% in the USA (Reizner 1994). The UK has a very different
pattern of distribution of lesions, with only 13% appearing on the
head and neck and 67%occurring on the lower limbs (Eedy 1987).
Generally, few Bowen’s Disease lesions occur on the trunk, but a
study in Japan (Kovacs 1996) and another on white people living
in Hawaii (Reizner 1994) found a notably higher predominance
of lesions on the trunk, 35% and 26% respectively.
Impact
In general, people with Bowen’s Disease have an excellent prog-
nosis because the disease is typically slow growing and responds
favourably to treatment although, a significant number of lesions
of Bowen’s Disease are not treated due to its relatively benign na-
ture and the demographics of the participants with the condition.
The risk of progression of Bowen’s Disease to invasive squamous
cell carcinoma (SCC) is generally considered to be about 3%, of
which approximately one third may metastasise (spread to other
areas) (Cox 1999; Arlette 2004). These figures are high compared
to what is actually seen in clinical practice and may reflect the
inclusion of mucosal and anogenital Bowen’s Disease where there
is a higher risk of transformation and metastasis.
Bowen’s Disease may represent a risk marker for other non-
melanoma skin cancers. Studies that have investigated this associ-
ation report about one third of people have another NMSC (most
commonly basal cell carcinomas (BCC)) at the time of diagnosis
(Thestrup-Ped 1988; Reizner 1994). There is also a 4.3 times in-
creased risk of developing subsequent NMSC (Jaeger 1999).
There has been much discussion about an association between
Bowen’s Disease and internal malignancies, with several studies
suggesting a significant relationship between the two (Cox 1999).
However, a 1989meta-analysis of 12 studies (10 cohort and 2 case-
control studies) found no significant relationship between the 2
(Lycka 1989). This result was subsequently confirmed by two large
population-based cohort studies, one in Denmark (Jaeger 1999)
and the other in the USA. It is now generally accepted that there is
no relationship between Bowen’s Disease and internal malignan-
cies, and therefore, routine investigation for internal malignancies
is not justified (Cox 1999).
Causes
Bowen’s Disease predominantly occurs in older age groups and on
areas of the body subjected to chronic sun exposure (head andneck,
and lower legs inwomen), suggesting a causal relationship between
chronic exposure to ultraviolet light radiation and Bowen’s Dis-
ease (Eedy 1987; Thestrup-Ped 1988; Kossard 1992; Cox 1994;
Reizner 1994; Kovacs 1996). Exposure to arsenic through well
water, older medications and occupational chemicals have been
associated with the development of Bowen’s Disease, with a typical
time lag of more than ten years between exposure and develop-
ment of lesions (Cox 1999; Arlette 2004). Viral causes include the
human papillomavirus (HPV) and the human herpes virus type
8, although various studies report conflicting results about the fre-
quency with which these agents are detected in Bowen’s Disease
lesions. Immunosuppression, either congenital, acquired or thera-
peutic, has also been associated with Bowen’s Disease (Cox 1999).
Although not the subject of this review, it is interesting to note
that viral causes are involved in almost 100% of cases of mucosal
and anogenital Bowen’s Disease.
Description of the intervention
There are a range of treatment options for Bowen’s disease, includ-
ing:
• topical therapies such as 5-fluorouracil and imiquimod;
• surgical interventions such as excision, cryotherapy,
curettage and cautery, and Mohs’ surgery;
• light based therapies such as laser therapy and
photodynamic therapy;
• radiotherapy.
How the intervention might work
Photodynamic therapy
Photodynamic therapy is a non-ionising radiation treatment using
the interaction between visible light and tumour sensitising agents
to generate cell death.
5-Fluorouracil
The primary mechanism of action of 5-fluorouracil is thought
to be inhibition of DNA synthesis by competitive inhibition of
thymidylate synthetase.
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Imiquimod
Imiquimod is an immune response modifier that has been shown
to induce cytokines that promote a TH1 lymphocyte or cell-me-
diated immune response.
Mohs’ micrographic surgery
Mohs’ micrographic surgery is a technique whereby 100% of the
surgical margin is examined bymapping horizontal frozen sections
from successive excision layers until clearance is achieved.
Radiotherapy
Radiotherapy works by destroying the cancer cells in the treated
area using high energy X-rays.
Laser surgery
Laser surgery uses a highly focused beam of light that destroys only
the cancer cells.
Cryotherapy
Cryotherapy uses liquid nitrogen to destroy tissue by freezing it to
-196oC.
Curettage and cautery
Electrodessication and curettage are generally known as ’scraping
or burning-off of skin growths’. Curettage is performed under lo-
cal anaesthesia. The curette is either an oval, semi sharp, spoon-
shaped instrument or an open ring connected to a handle. The
curette is designed to cut through abnormally soft or friable tissue
with minimum force so that the diseased tissue can be selectively
removed. Curettage should be combined with subsequent electro-
cautery which destroys additional tissue.
Why it is important to do this review
The relative effectiveness of the available treatments is not known
for Bowen’s disease. Treatment of Bowen’s Disease needs to bal-
ance the burden of treatment against its benefit, particularly as the
disease mainly affects the elderly and is predominantly slow grow-
ing in nature. Some Bowen’s Disease lesions may deserve special
consideration, for example, lesions of the lower limb and especially
larger lesions, due to the potential for poor healing in the former
and the high recurrence rates in the latter.
Given these issues, this review will attempt to address the follow-
ing:
(1) What are the most effective treatments for Bowen’s disease,
with the fewest side effects?
(2) How do the various therapies compare in the following par-
ticipant subgroups:
• participants with lower leg lesions (i.e. located below the
knee)?
• participants with lesions > 2cm2?
• patients with medical co-morbidities leading to poor
wounding healing and/or age greater than 70 years?
O B J E C T I V E S
To assess the effects of therapeutic interventions for Bowen’s dis-
ease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) of any design
Types of participants
People with histologically proven Bowen’s Disease. People with
genodermatoses (genetic disorders of the skin), mucosal, or
anogenital Bowen’s Disease will be excluded.
Types of interventions
Any interventions for the treatment of Bowen’s Disease, including:
Surgical
1. Surgical excision
2. Mohs’ micrographic surgery
Destructive
1. Curettage and cautery/electrodesiccation
2. Cryosurgery - any number of cycles
3. Photodynamic therapy
4. Laser surgery
5. Radiotherapy
Other techniques
1. Topical therapy e.g. imiquimod, 5 fluorouracil
The comparators will be any other type of accepted and commonly
used treatment modality, any interventions compared to control
(placebo/no treatment), or different dosages/durations of the same
interventions.
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Types of outcome measures
Primary outcomes
(i) Complete clearance of the lesion
Ideally, clearance of the lesion will be determined by histology, but
clinical clearance at follow-up will be accepted.
Since a number of treatments require more than one cycle of ther-
apy we will look at:
• Number of patients with clearance after first treatment
cycle;
• Recurrence at 12 months
Secondary outcomes
(i)Number of patients with clearance after each treatment
cycle
(ii)Number of treatment cycles needed to achieve clearance
(iii)Recurrence at >12 months
(iv) Cosmetic outcome
This will be assessed using a recognised and validated instrument
to measure cosmesis
(v) Consumer satisfaction with treatment modality and/or
cosmesis and/or pain at site
We expect this to be recorded on a Likert or Likert-like scale.
(vi) Time to complete healing of lesion following treatment
This will be determined by clinical examination and / or by par-
ticipant assessment through a diary or similar mechanism.
(vii) Quality of life
This will be determined by any validated quality of life instrument
(viii) Adverse outcomes
These will be categorised using the following system:
a) none;
b) mild: transient, requires no treatment, non interference with
social/occupational function;
c) moderate: requires simple treatment, interferes with social/oc-
cupational function;
d) severe: requires vigorous treatment, hospitalisation, and inter-
rupts social/occupational function.
(ix) Recurrence of Bowen’s disease in same site
This will be determined by clinical examination
Search methods for identification of studies
Electronic searches
We shall search for relevant published trials in:
• the Cochrane Skin Group Specialised Register;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library (last update);
• MEDLINE (from 2003) and EMBASE (from 2005);
• PsycInfo and LILACS (Latin American and Caribbean
Health Science Information database) from inception
• CISCOM, ISI Science Citation Index (on BIDS) ISI web
of science.
The UK Cochrane Centre has an ongoing project to systemati-
cally search MEDLINE and EMBASE for reports of trials which
are then included in the Cochrane Central Register of Controlled
Trials. Searching has currently been completed in MEDLINE to
2003 and in EMBASE to 2005. Further searching will be under-
taken for this review by the Cochrane Skin Group to cover the
years that have not been searched by the UKCC.
We have devised a draft search strategy for RCTs for MEDLINE
(OVID) which is displayed in Appendix 1. This will be modified
to include additional search termswhere necessary andwill be used
as the basis for designing search strategies for the other databases
listed.
Ongoing Trials
We shall search for ongoing trials in:
• The metaRegister of Controlled Trials on www.controlled-
trials.com
• The U.S National Institutes of Health register on
www.clinicaltrials.gov
• The Australian Clinical Trials Registry on
www.anzctr.org.au
• The WHO portal on www.who.int/trialsearch/
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• The Ongoing Skin Trials Register on
www.nottingham.ac.uk/ongoingskintrials
Searching other resources
Grey Literature
We shall attempt to find unpublished studies through correspon-
dence with key authors publishing in this area, and by contacting
pharmaceutical companies who produce relevant products. The
possible companies include:
• Valeant Pharmaceuticals Australasia Pty Ltd (5-fluorouracil,
Efudex)
• ICN (5-fluorouracil, Efudex)
• Roche (5-fluorouracil, Efudix)
• Allergan (5-fluorouracil, Fluoroplex)
• Dermik (5-fluorouracil, Carac)
• 3M Pharmaceucticals and Graceway Pharmaceuticals
(imiquimod, Aldara)
• Sigma (5-Aminolevulinic acid, 5-AlA)
• Biosynth (5-Aminolevulinic acid, 5-Ala, delta-
Aminolevulinic acid)
• DUSA Pharmaceuticals (photodynamic therapy)
• Galderma (photodynamic therapy, Metvix-PDT)
Additional pharmaceutical companies who produce any further
products identified during the process of undertaking this review
will also be contacted.
Reference lists
We shall scan the bibliographies of published studies (both in-
cluded and excluded studies) and reviews for possible references
to RCTs.
Correspondence
We shall try to identify unpublished or on-going trials by corre-
spondence with authors and pharmaceutical companies, as listed
above under Grey Literature.
Adverse events
Wewill identify reports of adverse events in included and excluded
studies, and through searching the web sites of the following ad-
verse outcome reporting agencies:
• The European Medicines Agency http://emea.europa.eu
• The Therapeutic Goods Administration of Australia
www.tga.gov.au
• The Medicines and Healthcare products regulatory Agency
http://medicines.mhra.gov.uk
• The U.S. Food and Drug Administration www.fda.gov/
medwatch
Language
We will impose no language restrictions and we shall seek transla-
tions where necessary.
Data collection and analysis
Selection of studies
Two authors (FB-H and JL-B) will review the titles and abstracts
identified from the searches. Studies that are clearly not ran-
domised controlled trials of treatments for Bowen’s Disease will be
excluded. The same two authors will independently assess the full
text version of the remaining studies against the pre-defined selec-
tion criteria. We will resolve any differences of opinion through
discussion with the third author (DW).
Data extraction and management
Two authors (FB-H and JL-B) will independently extract the data
using a specially designed data extraction form. The third author
(DW) will resolve any differences of opinion. One author will
enter data into RevMan (FB-H).
Cosmetic outcome, consumer satisfaction with cosmesis, con-
sumer pain ratings, and severity of adverse effects are all ordinal
data outcomes. Where possible, we will translate these outcomes
into dichotomous data and we will record both the original and
translated results.
We will express all other outcomes as actual or percentage differ-
ences between treatment arms.
Assessment of risk of bias in included studies
The assessment of the methodological quality of included studies
will include an evaluation of the following components of internal
and external validity for each included study, since there is some
evidence that these are associated with biased estimates of treat-
ment effect (Juni 2001):
(a) the method of generation of the randomisation sequence
(b) the method of allocation concealment - we will consider it
’adequate’ if the assignment could not be foreseen
(c) who was blinded and not blinded (participants, clinicians, out-
come assessors), if appropriate
(d) the number of participants lost to follow-up in each treatment
arm, and if the reasons for losses were adequately reported
(e) whether all participants were analysed according to the groups
to which they were initially randomised (intention to treat prin-
ciple)
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In addition, we will assess the following:
(f ) baseline comparability between treatment arms
Measures of treatment effect
Wewill express the results as risk ratios (RR) with 95% confidence
intervals (CI) for dichotomous outcomes; and we will use number
needed to treat (NNT) to express the relative benefit (or otherwise)
of the various treatment options where appropriate, for a range of
plausible control event rates.
We shall usemeandifferences (MD)with 95%CI to express results
for continuous outcomes where the samemeasurement scales have
been used across trials, and we shall use standardised mean differ-
ences (SMD) to express results for continuous outcomeswhere dif-
ferent, but comparable, measurement scales have been used across
trials.
We will analyise cross-over trials using techniques appropriate for
paired designs, for appropriate outcome measures.
For time-to-event data, we will express the results as hazard ratios
with 95% CI.
We will estimate the log hazard ratio and its variance with a Mi-
crosoft Excel spreadsheet authored byMatthew Sydes (Cancer Di-
vision) in collaboration with theMeta-analysis Group of theMRC
Clinical Trials Unit, London, which is based on Parmar’s methods
(Parmar 1998). We will calculate the log hazard ratio and its vari-
ance either using directly extracted data or estimated from survival
curves.Where ordinal data cannot be dichotomised, wewill report
a qualitative summary with presentation of the data in tables of
figures as appropriate.
We shall translate ordinal outcomes (cosmetic outcome, consumer
satisfaction with cosmesis, consumer pain ratings, and severity
of adverse effects) into dichotomous data using established cut
points, where possible.
Unit of analysis issues
Wewill analyse internally controlled trials using appropriatemeth-
ods for paired designs and we will not pool these studies with stud-
ies of other designs. We will not include non-randomised con-
trolled trials in the analysis, but we will comment on them in
the discussion. If a trial contains multiple intervention groups, we
shall make pairwise comparisons of interventions versus placebo
or other interventions.
Dealing with missing data
Wewill deal withmissingdata due to participant drop-out through
intention-to-treat analysis. In other words, we shall analyse all trial
participants according to the group to which they were assigned
and we will include all participants in the analysis irrespective of
whether their outcomes were actually collected. For dichotomous
outcomeswewill assume that all the ’missings’ had a poor outcome.
For continuous outcomes, wewill use the ’last recorded value taken
forward’ approach. We shall contact trial authors of studies less
than 15 years old to provide information about participant drop-
out and missing statistics such as standard deviations.
Assessment of heterogeneity
Wewill assess heterogeneity, or variability between studies visually
and we will quantify using the I2 statistic. I2 describes the per-
centage of the variability in effect estimates that is due to variabil-
ity among the studies rather than chance (Higgins 2008). If I2 is
>85% then we will not perform meta-analysis.
Assessment of reporting biases
We will use funnel plots to alert us to the potential of publication
bias, although we are aware that factors other than publication bias
can cause asymmetric funnel plots, and conversely, publication
bias may be present with a symmetrical funnel plot.
Data synthesis
If the included studies have sufficient homogeneity, we will per-
form ameta-analysis to calculate aweighted treatment effect across
trials. The degree of heterogeneity will determine if a fixed effect
or random effects model is used. If it is not possible to perform a
meta-analysis we shall summarise the data for each trial narratively.
Subgroup analysis and investigation of heterogeneity
If substantial heterogeneity exists (I2 > 50%) between studies for
the primary outcome we will explore heterogeneity by examining
the effects of excluding study subgroups e.g. those studies with
lower reported methodological quality (i.e. studies that did not
clearly report randomisation, blinding and which do not have
an intention-to-treat analysis), we shall also investigate potential
causes of the heterogeneity, including dosage and duration of treat-
ment, lesion characteristics (size, body site) and age groups of par-
ticipants.
We shall conduct subgroup analyses where adequate information
is available. The groups will include: body site of lesion (particu-
larly lower leg lesions, i.e. located below the knee); size of lesion
(particularly lesions > 2cm), age of the participants (particularly
those over 70 years of age); and participants with medical co-mor-
bidities (particularly those that could affect wound healing).
Sensitivity analysis
We plan to conduct sensitivity analyses to assess the robustness
of the results of the review, relative to the key assumptions and
decisions made during the progress of the review, as defined in
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2008)
6Interventions for Bowen’s Disease (Protocol)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Adverse outcomes
We shall record the appropriateness and relevance of the methods
used to detect adverse events, and the adequacy of the reporting.
We shall summarise and describe the information qualitatively.
Other
In instances of uncertainty, clarification will be sought from trial
authors or investigators. The consumer in our team (JD) will en-
sure the final review is relevant, readable and understandable.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. humans.sh.
10. 8 and 9
11. Bowen’s disease.mp. or exp Bowen’s Disease/
12. bowenoid papulosis.mp.
13. morbus bowen.mp.
14. exp Carcinoma, Squamous Cell/ or in situ squamous cell carcinoma.mp.
15. intraepidermal squamous cell carcinoma.mp.
16. 11 or 12 or 13 or 14 or 15
17. cryosurgery.mp. or exp Cryosurgery/
18. cryotherapy.mp. or exp Cryotherapy/
19. curettage.mp. or exp Curettage/
20. fluorouracil.mp. or exp Fluorouracil/
21. 5-fluorouracil.mp.
22. efudex.mp.
23. 5-FU.mp.
24. photochemotherapy.mp. or exp Photochemotherapy/
25. photodynamic therapy.mp.
26. exp Aminolevulinic Acid/ or aminolaevulinic acid.mp.
27. (ALA or ALA-PDT).mp. [mp=title, original title, abstract, name of substance word, subject heading word]
28. imiquimod.mp.
29. aldara.mp.
30. liquid nitrogen.mp.
31. excision.mp.
32. mohs surgery.mp. or exp Mohs Surgery/
33. moh’s surgery.mp.
34. laser surgery.mp. or exp Laser Surgery/
35. carbon dioxide laser.mp.
36. argon laser.mp.
37. Nd:YAG laser.mp.
38. lasers.mp. or exp Lasers/
39. radiotherapy.mp. or exp Radiotherapy/
40. recombinant interferon gamma.mp. or exp Interferon-gamma, Recombinant/
41. interferon type ii.mp. or exp Interferon Type II/
42. interferon gamma.mp.
43. interferons.mp. or exp Interferons/
44. interferon alfa-2b.mp. or exp Interferon Alfa-2b/
45. interferon alpha-2b.mp.
46. interferon.mp.
47. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46
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48. 10 and 16 and 47
H I S T O R Y
Protocol first published: Issue 3, 2008
C O N T R I B U T I O N S O F A U T H O R S
Draft the protocol: FB-H, JL-B, DA, DW
Search for trials: FB-H, JL-B
Obtain copies of trials: FB-H, JL-B
Select which trials to include: FB-H, JL-B, arbitrator in case of disagreement: DW
Extract data from trials: FB-H, JL-B
Enter data into RevMan: FB-H
Conduct analysis: FB-H, JL-B
Interpret analysis: FB-H, JL-B, DA, DW
Draft final review: FB-H, JL-B
Update the review: FB-H, JL-B
D E C L A R A T I O N S O F I N T E R E S T
None known
S O U R C E S O F S U P P O R T
Internal sources
• The University of Nottingham, UK.
External sources
• No sources of support supplied
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